Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02247804 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
A Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 594
- Enrollment target
- 20
- Study locations
NCT02247804: Completed Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Allergan.
NCT02247804 is a Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle that has completed, run by Allergan. The registered enrollment target is 594 participants, above the 267-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (122% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02247804, a Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 594 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
Primary Outcome
IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. A mixed-effects model with repeated measures (MMRM) was used for analyses. A negative change from baseline indica
Conditions Studied
Interventions
- DRUG Bimatoprost SR
- DRUG Active Comparator: Timolol 0.5%
- OTHER Sham: Applicator Without Needle
- DRUG Timolol Vehicle (placebo)
Study Locations (20)
California
- Lugene Eye Institute - Glendale
- Lakeside Vision Center - Irvine
- Hamilton Glaucoma Center, Shiley Eye Center UCSD - La Jolla
- Atlantis Eye Care - Long Beach
- Glaucoma Institute of Beverly Hills - Los Angeles
- Montebello Medical Eye Center Inc. - Montebello
- Stanford University - Palo Alto
- Foothill Eye Institute - Pasadena
- Martel Eye Medical Group - Rancho Cordova
- Grutzmacher, Lewis and Sierra, Inc. - Sacramento
- Pacific Eye Associates - San Francisco
Florida
- Palm Beach Eye Center, INC - Atlantis
- Nature Coast Clinical Research - Crystal River
- Levenson Eye Associates - Jacksonville
- East Florida Eye Institute - Stuart
- International Research Center - Tampa
Arizona
- Arizona Glaucoma Specialists - Phoenix
Colorado
- Eye Associates of Colorado Springs - Colorado Springs
Georgia
- Coastal Research Associates, LLC - Roswell
Illinois
- Chicago Eye Specialists - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2014-12-15 |
| Est. Completion | 2019-07-19 |
| Phase | Phase 3 |
What the finished NCT02247804 record still lists
NCT02247804 is an interventional study that assigns participants to a tested intervention. The registered 594 participants enrollment target is mid-sized for trials with a published cap, above the 267-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (122% higher).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 4 interventions - of which Bimatoprost SR is the first listed.
NCT02247804 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02247804 about?
NCT02247804 is a clinical study titled "Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension". This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
What is the current status of trial NCT02247804?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 594 participants. The study started on 2014-12-15. Estimated completion is 2019-07-19.
What conditions does trial NCT02247804 study?
This clinical trial studies the following conditions: Ocular Hypertension, Glaucoma Open-Angle.
What interventions are being tested in trial NCT02247804?
The interventions under investigation include: Bimatoprost SR (DRUG), Active Comparator: Timolol 0.5% (DRUG), Sham: Applicator Without Needle (OTHER), Timolol Vehicle (placebo) (DRUG).
Who is sponsoring clinical trial NCT02247804?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02247804 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02247804's enrollment target sits among peer trials
594 7th of 54 higher than 48 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT05867420 · 594 participants · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- NCT06890884 · 594 participants · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI